insights_auto
Outlook: 37.5% bullish·15.6% bearish
Go to analysischevron_right
ARGX:NASDAQ
argenx SE - ADR
825,03 $
arrow_upward
+0,78%(+6,40) 1D
825,03 $
0,00% (0,00)
bedtimeAfter hours
Closed: 9 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARGX...
Open
821,96 $
High
826,78 $
Low
805,07 $
Mkt. cap
50,06 մլրդ
Avg. vol.
333,30 հզր
Volume
512,25 հզր
P/E ratio
31,34
52-wk high
1 072,75 $
52-wk low
661,85 $
EPS
26,32 $
Beta
0,45
Shares outstanding
62,89 մլն
No. of employees
2 հզր
Open
821,96 $
High
826,78 $
Low
805,07 $
Mkt. cap
50,06 մլրդ
Avg. vol.
333,30 հզր
Volume
512,25 հզր
P/E ratio
31,34
52-wk high
1 072,75 $
52-wk low
661,85 $
EPS
26,32 $
Beta
0,45
Shares outstanding
62,89 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
Simply Wall Street
·
18 րոպե առաջ
Could A Halted Sjögren Trial Alter The Investment Case For argenx Stock?
Stock Traders Daily
·
4 ժամ առաջ
Price-Driven Insight from (ARGX) for Rule-Based Strategy
Yahoo Finance
·
4 ժամ առաջ
argenx (ENXTBR:ARGX) Stock May Be Fully Priced After Its 185% Run
Zacks
·
23 ժամ առաջ
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE - ADR